U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07116395) titled 'Prospective Study: TXA, Anticoagulant, Orthopaedic Trauma' on July 29.
Brief Summary: Tranexamic acid, an anti-fibrinolytic agent, is commonly given after induction of general anesthesia in patients undergoing hip and knee arthroplasty. This medication has been associated with decreased blood loss during these procedures, decreased rate of blood transfusion, decreased hospital costs, and no increased risk of thrombotic complication. Given the safety and efficacy of this medication in one subspeciality of orthopedics, it is warranted to investigate the use of it in another subspeciality where blood loss is also of concern. It is also...